254 related articles for article (PubMed ID: 33787090)
21. The new era of immune checkpoint inhibition and target therapy in early-stage non-small cell lung cancer. A review of the literature.
Catania C; Muthusamy B; Spitaleri G; Del Signore E; Pennell NA
Clin Lung Cancer; 2022 Mar; 23(2):108-115. PubMed ID: 34952792
[TBL] [Abstract][Full Text] [Related]
22. Surgical Perspective on Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer.
Lee JM; Tsuboi M; Brunelli A
Ann Thorac Surg; 2022 Oct; 114(4):1505-1515. PubMed ID: 34339672
[TBL] [Abstract][Full Text] [Related]
23. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant anti-programmed death-1 immunotherapy by pembrolizumab in resectable non-small cell lung cancer: First clinical experience.
Eichhorn F; Klotz LV; Kriegsmann M; Bischoff H; Schneider MA; Muley T; Kriegsmann K; Haberkorn U; Heussel CP; Savai R; Zoernig I; Jaeger D; Thomas M; Hoffmann H; Winter H; Eichhorn ME
Lung Cancer; 2021 Mar; 153():150-157. PubMed ID: 33529989
[TBL] [Abstract][Full Text] [Related]
25. Perioperative Immunotherapy for Non-Small Cell Lung Cancer: Practical Application of Emerging Data and New Challenges.
D'Aiello A; Stiles B; Ohri N; Levy B; Cohen P; Halmos B
Clin Lung Cancer; 2024 May; 25(3):197-214. PubMed ID: 38462413
[TBL] [Abstract][Full Text] [Related]
26. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
Kang J; Zhang C; Zhong WZ
Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
[TBL] [Abstract][Full Text] [Related]
27. Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial.
Heymach JV; Mitsudomi T; Harpole D; Aperghis M; Jones S; Mann H; Fouad TM; Reck M
Clin Lung Cancer; 2022 May; 23(3):e247-e251. PubMed ID: 34819266
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.
Chen J; Alduais Y; Chen B
Cell Transplant; 2021; 30():9636897211041587. PubMed ID: 34606729
[TBL] [Abstract][Full Text] [Related]
29. Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2)
Xiong L; Li R; Sun J; Lou Y; Zhang W; Bai H; Wang H; Shen J; Jing B; Shi C; Zhong H; Gu A; Jiang L; Shi J; Fang W; Zhao H; Zhang J; Wang J; Ye J; Han B
Oncologist; 2019 Feb; 24(2):157-e64. PubMed ID: 30158288
[TBL] [Abstract][Full Text] [Related]
30. Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.
Ma T; Wen T; Cheng X; Wang Y; Wei P; Yang B; Yi L; Wang X; Yan Z; Wang J; Liu Z
Lung Cancer; 2022 Oct; 172():43-52. PubMed ID: 35988509
[TBL] [Abstract][Full Text] [Related]
31. Impact of chronic obstructive pulmonary disease on the efficacy and safety of neoadjuvant immune checkpoint inhibitors combined with chemotherapy for resectable non-small cell lung cancer: a retrospective cohort study.
Dong W; Yin Y; Yang S; Liu B; Chen X; Wang L; Su Y; Jiang Y; Shi D; Sun D; Qin J
BMC Cancer; 2024 Jan; 24(1):153. PubMed ID: 38291354
[TBL] [Abstract][Full Text] [Related]
32. [The outcome and safety of neoadjuvant PD-1 blockade plus chemotherapy in stage Ⅱ~Ⅲ non-small cell lung cancer].
Liu YT; Gao YS; Mao YS; Jiang J; Yang L; Yang JL; Hu XS; Zhou SY; Qin Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Jun; 42(6):480-485. PubMed ID: 32575944
[No Abstract] [Full Text] [Related]
33. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Wu S; Hu C; Wu F; Wu Y; Liu P
Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783
[TBL] [Abstract][Full Text] [Related]
34. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
35. Impact of Neoadjuvant Immune Checkpoint Inhibitors on Surgery and Perioperative Complications in Patients With Non-small-cell Lung Cancer: A Systematic Review.
Takada K; Takamori S; Brunetti L; Crucitti P; Cortellini A
Clin Lung Cancer; 2023 Nov; 24(7):581-590.e5. PubMed ID: 37741717
[TBL] [Abstract][Full Text] [Related]
36. [Evaluation of Response to Immune Checkpoint Inhibitor Monotherapy or
Combination with Chemotherapy for Patients with Advanced Non-small Cell Lung Cancer and High PD-L1 Expression].
Li H; Qin N; Yu M; Ma L; Wu Y; Zhang H; Zhang X; Li X; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Mar; 24(3):161-166. PubMed ID: 33819965
[TBL] [Abstract][Full Text] [Related]
37. Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer.
Hong T; Sun T; Zhang M; Liu X; Yuan Y; Dolo PR; Chen B; Zhang H
Thorac Cancer; 2021 Oct; 12(20):2796-2802. PubMed ID: 34463034
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant immunotherapy for advanced, resectable non-small cell lung cancer: A systematic review and meta-analysis.
Wu Y; Verma V; Gay CM; Chen Y; Liang F; Lin Q; Wang J; Zhang W; Hui Z; Zhao M; Wang J; Chang JY
Cancer; 2023 Jul; 129(13):1969-1985. PubMed ID: 36994945
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial.
Shu CA; Gainor JF; Awad MM; Chiuzan C; Grigg CM; Pabani A; Garofano RF; Stoopler MB; Cheng SK; White A; Lanuti M; D'Ovidio F; Bacchetta M; Sonett JR; Saqi A; Rizvi NA
Lancet Oncol; 2020 Jun; 21(6):786-795. PubMed ID: 32386568
[TBL] [Abstract][Full Text] [Related]
40. Perioperative Immunotherapy in Non-Small Cell Lung Cancer.
O'Brien J; Bodor JN
Curr Treat Options Oncol; 2023 Dec; 24(12):1790-1801. PubMed ID: 38091187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]